Stifel Nicolaus Sticks to Their Buy Rating for Alkermes (ALKS)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Matteis is a 3-star analyst with an average return of 1.2% and a 41.20% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Alkermes, Neurocrine, and uniQure.
In addition to Stifel Nicolaus, Alkermes also received a Buy from UBS's Ashwani Verma in a report issued on June 17. However, on June 10, RBC Capital maintained a Hold rating on Alkermes (NASDAQ: ALKS).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
6 minutes ago
- Bloomberg
Fed's Cook Defies Trump Pressure, Possible UK Home Tax, Vape Ban Failings
Your morning briefing, the business news you need in just 15 minutes. On today's podcast: (1) Federal Reserve Governor Lisa Cook signaled her intention to remain at the central bank, defying calls for her resignation by President Donald Trump over allegations of mortgage fraud. (2) Most Federal Reserve officials highlighted inflation risks as outweighing concerns over the labor market at their meeting last month, as tariffs fueled a growing divide within the central bank's rate-setting committee. (3) The NASDAQ declined for the second straight day yesterday, with MAG 7 stocks on their longest losing streak since April. Futures are currently pointing higher for the tech-heavy index, but this week's dip has raised questions if the rally in the sector has gone too far, too fast. (4) UK Chancellor of the Exchequer Rachel Reeves is considering taxing high-value family homes at the point of sale as she looks for ways to plug a multibillion-pound hole in the upcoming budget. (5) European leaders are discussing a security guarantee for Ukraine that would commit Kyiv's allies to decide within 24 hours whether to provide military support to the country if it's again attacked by Russia. (6) A UK ban on disposable vapes is failing to stop users treating refillable devices as if they are still throwaway products, new research shows.
Yahoo
27 minutes ago
- Yahoo
Cantargia Publishes Half-Year Report 2025
LUND, SE / / August 21, 2025 / Cantargia AB (publ) [Nasdaq Stockholm:CANTA] (Cantargia) today issued the interim report for January to June 2025. "I started my tenure as interim CEO with a strong focus on looking to deliver at least one transformative transaction during 2025. I am delighted for all Cantargia's stakeholders, including our loyal shareholders, our employees and patients in need, that we have been able to deliver on this goal with the Otsuka agreement. Not only does the deal bring significant non-dilutive financial resources but, equally importantly, it provides clear validation of Cantargia's technology and platform. Cantargia is now on a solid footing and our next important task is to prioritize those programs and activities on which we will focus our resources going forward." said Damian Marron, Interim CEO of Cantargia. Significant events in the second quarter Cantargia appointed Morten Lind Jensen as Chief Medical Officer. Treatment resistant atopic dermatitis (AD) was selected as second indication for CAN10's phase 2 program. Pharmacokinetic modelling confirmed the choice of Q4W dosing in phase 2 for CAN10. US FDA awarded nadunolimab Fast Track Designation. Cantargia signed a loan facility of SEK 50 million. Significant events after the end of the period Otsuka Pharmaceuticals acquired CAN10 for an upfront of MUSD 33 plus an additional MUSD 580 in potential milestone payments and up to double digit earn-outs on future sales. The deal is expected to close in Q3 2025. Preliminary results from the TRIFOUR phase 2 study in TNBC did not demonstrate a difference in overall response rate (ORR) between nadunolimab in combination with chemotherapy vs. chemotherapy alone. Cantargia appointed Dr Hilde H. Steineger as new CEO effective from September 1, 2025. Financial information Second quarter 2025 (April 1 - June 30) Net sales: SEK 0.0 M (0.0) Operating loss: SEK -39.5 M (-43.8) Loss after tax: SEK -39.3 M (-43.3) Loss per share, before and after dilution: SEK -0.16 (-0.24) First six months of 2025 (January 1 - June 30) Net sales: SEK 0.0 M (0.0) Operating loss: SEK -84.5 M (-85.5) Loss after tax: SEK -86.2 M (-80.2) Loss per share: before and after dilution, SEK -0.35 (-0.44) Equity/assets ratio: 34 (74) per cent Cash and cash equivalents: SEK 81.9 M (84.7) Short-term investments: SEK 0.0 M (20.0) In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference on August 21, at 3:00 p.m. CEST, where Cantargia's interim CEO Damian Marron, CBO Ton Berkien, and CFO Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session. If you wish to participate via audiocast, please use the link below. Via the web session you will be able to ask written questions. Webcast: . If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the .The webcast will also be available on demand on Cantargia's corporate website: For further information, please contactDamian Marron, Interim CEOTelephone: +46 (0)46-275 62 60E-mail: This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-21 07:00 CEST. About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. Cantargia has entered an agreement with Otsuka Pharmaceuticals on the acquisition of the CAN10 program. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at . AttachmentsInterim Report January June 2025 SOURCE: Cantargia View the original press release on ACCESS Newswire Sign in to access your portfolio
Business Insider
an hour ago
- Business Insider
Closing Bell Movers: Nordson up 5% after Q3 earnings beat
In the opening hour of the evening session, U.S. equity futures are little changed following more losses in regular trading on Wednesday – S&P 500 eminis are down two points at 6,411, Nasdaq 100 is flat at 23,325, and Dow Industrials is off by a decimal below 44,975. In commodities, WTI Crude Oil remains below $63 per barrel despite the rebound earlier while Precious Metals are slightly firmer – Gold at $3,390 and Silver just shy of $38 per ounce. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Energy, Staples, and Health Care were once again the leading sectors on the S&P 500 while Tech and Consumer Discretionary fared the worst. Target (TGT) and Estee Lauder (EL) led the sellers in the consumer space after reporting results. In Tech, the 'wobble' in the AI space continued as Palantir (PLTR) – by far the best performing component of the index this year through the first week of August – faltered once again and has now lost 18% off its highs. Ahead of the Jackson Hole address by Fed Chairman Powell on Friday, minutes from the prior FOMC decision saw committee members remaining concerned with inflationary pressures induced by the administration's trade policy, even though the Fed still sees longer-term expectations as 'well anchored'. On Thursday, investors will tune in for the release of the Weekly Jobless Claims from the Labor Department, along with the release of Flash PMI data as an early indicator of economic activity in August. Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGS – Nordson (NDSN) up 4.9% ALSO HIGHER – Savara (SVRA) up 3.2% after publishing IMPALA-2 clinical trial results in NEJM Flutter Entertainment (FLUT) up 2.5% after entering into new event contracts platform with CME (CME) CoreWeave, Inc. (CRWV) up 1.0% after Jane Street disclosed 5.4% passive stake DOWN AFTER EARNINGS – Coty Inc. (COTY) down 15.6% ALSO LOWER – Invivyd, Inc. (IVVD) down 14.0% after equity offering SharkNinja, Inc. (SN) down 2.2% after equity offering
